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Commentary
Angiotensin receptor blockers in heart failure after the
ELITE II trial
Ronnie Willenheimer
University Hospital Malmö, Malmö, Sweden
Abstract
Specific blockers of the angiotensin type 1 receptor, angiotensin receptor blockers (ARBs),
have been introduced as an alternative to angiotensin-converting enzyme inhibitors (ACEi)
for the treatment of heart failure. In comparison with ACEi, ARBs are better tolerated and
have similar effects on haemodynamics, neurohormones and exercise capacity. Early studies
have suggested that ARBs might have a superior effect on mortality. However, the first
outcome trial, ELITE II (Losartan Heart Failure Survival Study), did not show any significant
difference between losartan and captopril in terms of mortality or morbidity. This commentary
outlines the role of ARBs in the treatment of heart failure.
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Introduction
Angiotensin-converting-enzyme inhibitors (ACEi) improve
survival and decrease morbidity in patients with heart
failure (HF) [1], asymptomatic left ventricular systolic dys-
function [2], myocardial infarction [3] and high cardiovas-
cular risk [4]. However, there is a substantial under-use of
ACEi [5], due at least partly to the side effect profile and
concerns among many physicians of side effects [6].
Recently specific blockers of the angiotensin type 1
receptor (AT1 receptor), angiotensin receptor blockers
(ARBs), have been introduced as an alternative to ACEi.
Specific receptor blockade is potentially advantageous
compared with the non-specific interaction of ACEi and
expectations are high that ARBs will prove to be a useful
therapeutic option in HF.
Tolerance and efficacy of ARBs
ARBs are well tolerated, even by HF patients who cannot
tolerate an ACEi [7], and the side effects are at the
placebo level. The haemodynamic and neurohormonal
effects in HF patients are similar to those of ACEi [8–14],
and short-term studies have indicated that ARBs are at
least as efficacious as ACEi in terms of exercise capacity
and symptoms [10,11]. In a study of 844 HF patients a
dose-dependent increase in exercise capacity was
demonstrated for candesartan [15].
The ELITE trial
The first ELITE trial was conducted primarily to investigate
the safety and tolerability of the ARB losartan compared
with the ACEi captopril [16]. The study included 722
patients aged 65 years or more, with chronic symptomatic
HF and left ventricular systolic dysfunction. Patients were
randomized to losartan 50mg once daily or captopril
50mg three times daily, and followed up for 48 weeks.
The primary endpoint, a persistent increase in creatinine
concentration of at least 26.5mmol/l, was met by 10.5% of
the patients in both groups. Mortality and hospitalization2
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were secondary endpoints, and there was an unexpected
46% lower (P < 0.05) mortality from all causes as well as
significantly fewer hospitalizations in the losartan group.
Losartan was also tolerated significantly better.
The ELITE II trial
As a consequence of the ELITE results, the ELITE II trial
was initiated to examine whether losartan would be supe-
rior to captopril in terms of survival and morbidity in
patients with HF [17]. A total of 3152 patients with symp-
tomatic HF and a left ventricular ejection fraction of 40%
or less were randomized to either losartan 50mg once
daily (n=1578) or captopril 50mg three times daily
(n=1574). Patients were essentially naive for ACEi and
were stratified for beta-blocker use at baseline. The mean
age was 71.5 years; 70% were men. About half of the
patients were in New York Heart Association class II, ie
mildly symptomatic, and 45% were in class III, ie moder-
ately symptomatic. Approximately 80% had ischaemic
cause for the HF. The trial was completed when 530
deaths had occurred, after 555 days of mean follow-up.
There were no statistically significant differences between
the two treatment regimens with regard to the main efficacy
parameters. There were 280 and 250 deaths in the losartan
and captopril groups, respectively [hazard ratio losartan:cap-
topril 1.13, 95% confidence interval (CI) 0.95–1.35,
P=0.16]. There were 142 and 115 sudden deaths or resus-
citated cardiac arrests in the losartan and captopril groups,
respectively (hazard ratio 1.24, 95% CI 0.97–1.59,
P=0.08). The corresponding figures for the composite of
mortality and hospitalization from all causes were 752 and
707 events, respectively (hazard ratio 1.07, 95% CI
0.96–1.18,  P=0.21). Losartan was better tolerated than
captopril in that significantly fewer patients discontinued pre-
maturely owing to adverse events, excluding deaths, in the
losartan group (9.7% compared with 14.7%, P=0.001).
Ongoing trials with ARBs in heart failure
More information about the effects of ARBs on mortality
and morbidity in HF is expected soon. Table 1 depicts the
two mortality trials currently examining the effects of ARBs
in HF [18,19]. It should be noted that neither trial com-
pares an ARB with an ACEi directly. Instead, both investi-
gate the effects of an ARB compared with placebo on top
of standard HF therapy, including an ACEi. In addition, the
CHARM (candesartan in heart failure — assessment of
reduction in mortality and morbidity) trial compares can-
desartan with placebo in patients intolerant of ACEi and in
patients with a left ventricular ejection fraction of more
than 40% who are not on an ACEi [19].
What is the role of ARBs in the treatment of
heart failure?
Are ARBs better than, equal to or worse than ACEi?
The ELITE II trial is the only mortality trial comparing an
ARB and an ACEi that has been conducted up to now.
Consequently, there is no documentation that ARBs are
better than ACEi. ELITE II did not have the aim of demon-
strating non-inferiority for losartan compared with capto-
pril, and we do not know whether ARBs and ACEi are
equally efficacious. There is no evidence that ACEi are
better than ARBs, but given their superior documentation
in HF the general opinion is that ACEi remain first-line
therapy and that ARBs (i.e. losartan) might be considered
in patients who cannot tolerate an ACEi.
Although ARBs are directly compared with an ACEi in
ongoing mortality trials in high-risk myocardial infarction
patients [20], there is a need to perform a second mortal-
ity trial comparing an ARB and an ACEi directly in HF
patients. When designing such a trial there are some
important points to consider. Firstly, we do not know the
optimum dose of an ARB in terms of a survival effect in
HF, and it has been suggested that the losartan dose
used in the ELITE II trial might have been too low to show
superiority compared with captopril. The doses of ARBs
used in other ongoing trials in HF are equivalent to four
times that losartan dose [18,19]. Secondly, the timing
might be important. Theoretically ARBs might be superior
to ACEi especially when ACEi escape is present, in other
words when plasma levels of angiotensin II after some
duration of ACE inhibition return to pretreatment levels
[21,22]. This phenomenon seems to be present in around
Table 1
Ongoing mortality trials with ARBs in heart failure
Power primary endpoint Expected
Study Drugs Type of patients n reduction (%) Endpoints to be concluded
Val-HeFT Valsartan vs placebo Symptomatic HF,  5009 20 Total mortality 2000
(open ACEi) LVEF £40% Morbidity 906 deaths
CHARM Candesartan vs placebo Symptomatic HF + 16–20 CV mortality/ 2002
LVEF£40, on ACEi 2550 HF hospitalization
LVEF£40, ACEi intolerant 2000 (total mortality in
LVEF>40, no ACEi 2970 the combined arms)
LVEF, left ventricular ejection fraction; CV, cardiovascular; MI, myocardial infarction.3
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half of ACEi-treated HF patients, and these have a signifi-
cantly worse prognosis than those who have no escape
[23]. In the ELITE II trial, patients were essentially naive for
ACEi at baseline and could not have had any escape.
Although some might have developed escape during the
course of the trial, they would not have been exposed to
the drawbacks of the escape for a long time, because the
trial duration was only 1.5 years. If patients treated with an
ACEi for 2 years, for example, were to be randomized to
an ARB or an ACEi, there is theoretically a better chance
to show superiority for the ARB.
Are ARBs better than placebo?
A definite answer in terms of mortality and morbidity is not
yet available. The 95% CI of the ELITE II trial suggests that
losartan is at worst 35% less efficacious than captopril in
terms of mortality. This places losartan at approximately
the placebo level. A meta-analysis of observed mortality
data from losartan studies in HF, excluding the ELITE II
trial, included 1894 patients [24]. The odds of dying in the
losartan groups were 0.51 (95% CI 0.31–0.81) times
those of the controls. Because the control patients mainly
received an ACEi and only a minority received placebo,
this analysis is an underestimation of the efficacy of losar-
tan compared with placebo. However, this meta-analysis
does not give a true answer to the question. The CHARM
trial is designed to provide such an answer (Table 1) [19].
Is combined therapy better than an ACEi alone?
Combined therapy with an ACEi and an ARB permits both
an inhibition of the breakdown of bradykinin and a specific
AT1 receptor blockade, and might lead to more complete
inhibition of the renin–angiotensin system [20]. This might
provide benefits compared with monotherapy with either
agent. However, it is possible that combined therapy is less
effective than AT1 receptor blockade alone. Combined
therapy might lead to less formation of angiotensin II, in turn
causing less stimulation of the angiotensin type 2 receptors
than AT1 receptor blockade alone would. Because
angiotensin II might exert beneficial effects via the type 2
receptor this could be a drawback [20]. Furthermore, and
most importantly, combined therapy will most probably
cause the same side effects as ACE inhibition alone.
In terms of mortality and morbidity, no results are available
to answer this question. Relatively small, short-term
studies indicate that combined therapy might be beneficial
compared with ACEi alone in terms of neurohormonal acti-
vation, exercise capacity, left ventricular ejection fraction
and functional class [20]. The RESOLVD (Randomized
Evaluation of Strategies for Left Ventricular Dysfunction)
study included 768 patients with symptomatic HF [25].
Patients were randomized to monotherapy with candesartan,
a combination of candesartan and enalapril, or enalapril
alone. The aim of the study was to evaluate the effects on
exercise capacity, safety and tolerability, neurohormones,
ventricular function, quality of life and symptoms. There
were no between-group differences in terms of exercise
capacity or symptoms, whereas remodelling and neuroen-
docrine activation were significantly more attenuated with
the combined treatment compared with monotherapy with
either agent. The safety findings have been discussed. Of
patients receiving combined treatment (n=332), 8.7%
died; in patients given monotherapy with candesartan
(n=327), 6.1% died; whereas 3.7% of those treated with
enalapril in monotherapy (n=109) died. Differences
between groups were not statistically significant
(P=0.148). In addition, more hospitalizations were
observed in the candesartan groups, but with no signifi-
cant differences between groups. Because RESOLVD
was not designed as a mortality/morbidity study these
results should be interpreted cautiously.
A more definite answer to the question will be provided by
the Val-HeFT (Valsartan in Heart Failure Trial) [18] and
CHARM [19] trials (Table 1).
Are there differences in efficacy between ARBs?
There are some pharmacological differences between the
different ARBs [20], and individual studies have demon-
strated differences between ARBs in efficacy in lowering
blood pressure. However, a large meta-analysis has
pointed out that these differences are very small and prob-
ably clinically insignificant [26]. Whether there are any dif-
ferences between ARBs in terms of effects on mortality
and morbidity is as yet unknown.
Conclusions
ACEi are at present first-line drugs for the treatment of HF,
and ARBs can be considered in patients who cannot tol-
erate ACEi. Ongoing mortality trials in HF will elucidate
the role of combined ARB and ACEi therapy, as well as
the efficacy of ARBs compared with placebo. However, it
is also important to perform a second mortality trial that
directly compares an ARB and an ACEi in HF. When
designing such a trial the dosing and timing of therapy
should be carefully considered.
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